Live Breaking News & Updates on Cellect Biotechnology|Page 3
Stay updated with breaking news from Cellect biotechnology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Kadimastem hopes to turn corner with new management The Israeli stem cell technology company has named Asaf Shiloni CEO, after three new expert directors joined its board. Israeli stem cell technology company Kadimastem (TASE: KDST) has had a chequered history, with frequent going concern warnings on its financials, a downward drifting share price from its 2016 peak, and the departure last year of founder and CEO Yossi Ben-Yosef. The company now hopes to have turned a corner with the appointment of a new and experienced CEO and new directors. Kadimastem has named Asaf Shiloni, who was Vice President of Sales and Business Development at California-based PeproTech Inc., as CEO. PeproTech is the leading manufacturer of GMP Cytokines, vital components in all stem cell and cell therapy clinical trials. Kadimastem s announcement states that at PeproTech Shiloni established collaborations and joint ventures with top US stem cell companies and leading research labs worldwide, ....
Kadimastem Announces Executive Management Changes USA - English Accomplished US Life Science and Biotech Executive Asaf Shiloni Named New CEO Company Appoints Biotech Industry Leaders Ronen Twito, CPA as Co-Chairperson and Doron Birger and Ron Mayron to the Company s Board of Directors News provided by Share this article NESS ZIONA, Israel, Feb. 1, 2021 /PRNewswire/ Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, announces the appointment of Asaf Shiloni as CEO. This follows a series of executive management appointments in the last month including Mr. Ronen Twito, CPA, as Co-Chairperson of Kadimastem s Board of Directors, and new expert Board members, Mr. Doron Birger and Mr. Ron Mayron. All are highly accomplished biotechnology industry experts, dedicated to working in concert to secure a bright future for the company. ....